8 completed, 1 not yet recruiting, 1 terminated. 10 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Not yet recruiting 1 |
Follow brivaracetam: new trials by email Literature Review of brivaracetam trials Research Report on brivaracetam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epileptic Hippocampus in Alzheimer's Disease Brivaracetam - Alzheimer Disease, Mild Cognitive Impairment | Phase 1 / Phase 2 | Not yet recruiting | University of California, Los Angeles | 25 | 2026-01-01 | 2026-01-27 |
| Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury Brivaracetam, Placebo - Spinal Cord Injuries | Phase 1 / Phase 2 | Completed | University of Minnesota | 24 | 2021-02-01 | 2025-10-14 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy Brivaracetam - Epilepsy | Phase 2 | Completed | UCB Biopharma S.P.R.L. | 50 | 2018-06-01 | 2022-05-11 |
| A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting Brivaracetam, Lorazepam - Epilepsy | Phase 2 | Completed | UCB Biopharma S.P.R.L. | 46 | 2017-02-06 | 2020-12-16 |
| Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures Brivaracetam intravenous solution, Brivaracetam oral tablets, Phenytoin intravenous solution - Nonconvulsive Electrographic Seizures | Phase 2 | Terminated | UCB BIOSCIENCES, Inc. | 1 | 2014-03-01 | 2018-07-11 |
| Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy. Brivaracetam - Epilepsy | Phase 2 | Completed | UCB Pharma | 100 | 2011-07-01 | 2018-07-11 |
| A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures. Placebo, Brivaracetam - Epilepsy | Phase 2 | Completed | UCB Pharma | 210 | 2005-11-07 | 2018-10-02 |
| A Study of Brivaracetam in Subjects With Partial Onset Seizures Placebo, Brivaracetam - Epilepsy, Focal | Phase 2 | Completed | UCB Pharma | 157 | 2005-05-01 | 2015-04-13 |
| A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia) Placebo, Brivaracetam - Neuralgia, Postherpetic | Phase 2 | Completed | UCB Pharma | 152 | 2004-10-11 | 2019-01-31 |
| Effect of Brivaracetam in Photosensitive Epileptic Subjects Brivaracetam - Epilepsy | Phase 2 | Completed | UCB Pharma | 20 | 2002-09-01 | 2009-12-01 |
Epilepsy (6) · Alzheimer Disease (1) · Cognitive Dysfunction (1) · Epilepsies, Partial (1) · Neuralgia, Postherpetic (1) · Spinal Cord Injuries (1)
UCB Pharma (5) · UCB Biopharma S.P.R.L. (2) · UCB BIOSCIENCES, Inc. (1) · University of California, Los Angeles (1) · University of Minnesota (1)
United States (7) · Czechia (4) · Germany (4) · Spain (4) · Belgium (3) · France (3) · Mexico (3) · Poland (3) · United Kingdom (2) · Brazil (1) · Bulgaria (1) · Finland (1) · Hungary (1) · India (1) · Italy (1)
Keith A Vossel, MD, MSc (1) · Leslie Morse, DO (1) · Philipp von Rosenstiel, MD. (1) · Scott Falci, MD (1)
PMID 31937513, PMID 35285519, PMID 22813235, PMID 27265725, PMID 33461041, PMID 34570177, PMID 35196395
2004 (2), 2016 (1)